In patients with renal cell cancer (RCC), administration of a multikinase inhibitor Sunitinib capable of suppressing downstream STAT3 signaling resulted in decrease of MDSCs and Tregs along with increase of IFN-γ producing T cells (Ko et al., 2009; Ozao-Choy et al., 2009; Xin et al., 2009). This evidence concerns the gene STAT3 and renal cell adenocarcinoma.